GeoVax Labs Inc.'s Chief Scientific Officer Featured As Lecturer At American Society For Microbiology Conference

ATLANTA, GA--(Marketwired - September 04, 2014) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing HIV/AIDS vaccines, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D., presented a virtual lecture entitled "Working Towards an HIV Vaccine," on August 29, 2014 at the African Center for Integrated Laboratory Training in Sandringham, South Africa, sponsored by the American Society for Microbiology.

Dr. Robinson's lecture focused on the development of vaccines for control of the clade C pandemic in Africa and the clade B pandemic in the Americas. She reviewed clinical studies and vaccine responses that had correlated with control of infection in the first and only partially successful vaccine trial, conducted in Thailand. The lecture ended with a comparison of the distinctive features of the clade C vaccine advancing in human trials in Africa and the clade B vaccine that GeoVax is advancing in the Americas and the promise of these trials for success.

Dr. Robinson's lecture is available for viewing at www.geovax.com.

Dr. Robinson, formerly the Asa Griggs Candler Professor of Microbiology and Immunology at Emory University and Chief of the Division of Microbiology and Immunology at the Yerkes National Primate Research Center, is internationally recognized for her work on HIV/AIDS vaccines, her pioneering studies on the use of recombinant DNA for vaccination and her seminal studies on insertional mutagenesis and oncogene transduction in retroviral induced cancers. She received her Ph.D. from the Massachusetts Institute of Technology and her postdoctoral training at the Virus Laboratory, University of California Berkeley. Dr. Robinson is active on several editorial boards and has consulted for the U.S. National Institutes of Health, the U.S. Food and Drug Administration, the World Health Organization, and the Gates Foundation.

In 2013, the American Society for Microbiology (ASM) partnered with the South African National Health Laboratory Service (NHLS) to establish a Bio-Resource Center (BRC) at the NHLS campus in Sandringham, South Africa. The BRC builds on ASM's ongoing support to NHLS since 2010 via the African Centre for Integrated Laboratory Training (ACILT) program and expands on their shared commitment to provide high quality training and continuing education to local scientists and across Africa.

The ASM-NHLS Bio-Resource Center partnership co-sponsored two virtual scientific lectures, "Working Towards an HIV Vaccine" and "Tuberculosis Drug Discovery: Lessons Learned and Future," through the ASM Virtual Speaker Program. The lectures were given by two prestigious American Academy of Microbiology Fellows, Dr. Valerie Mizrahi, from the University of Cape Town and Dr. Harriet Robinson, from GeoVax Labs, Inc. The lectures took place on August 29, 2014 at the James Gear Auditorium of the NHLS premises and attracted a diverse audience, from faculty and graduate students from local universities to hospital and laboratory staff, and representatives from local NGOs. The aim of the virtual scientific lectures is to provide the audience with current information through an innovative experience and bring together the local scientific community to learn, discuss and share experiences.

About GeoVax
GeoVax Labs, Inc. (OTCQB: GOVX) is a biotechnology company developing vaccines to prevent, and treat, Human Immunodeficiency Virus (HIV) infections. GeoVax's unique, two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV antibody and anti-HIV T cell immune responses. GeoVax's DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Both the DNA and MVA express the three major proteins of the HIV virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. GeoVax's vaccines are unique in expressing virus-like particles that display the native form of the trimeric membrane-bound HIV-1 envelope glycoprotein. GeoVax's vaccines are currently being tested in human clinical trials, for both preventive and therapeutic applications. Clinical trials for GeoVax's preventive HIV vaccines have been conducted by the U.S. National Institutes of Health-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). Overall, GeoVax's vaccines, in various doses and combinations, have been tested in close to 500 humans. www.geovax.com

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent HIV/AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.